Export

ATC codes: C09DA07
Indication
Essential hypertension ICD11 code: BA00.Z
INN
Telmisartan + hydrochlorothiazide
Medicine type
Chemical agent
List type
Core
Formulations
Oral > Solid: 40 mg + 12.5 mg ; 80 mg + 12.5 mg ; 80 mg + 25 mg
EML status history
First added in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Sex
All
Age
Adolescents and adults
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for hydrochlorothiazide)
Patent information
Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Summary of evidence and Expert Committee recommendations
Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroup, C09CA Angiotensin II receptor blockers (ARBs), plain (for telmisartan); and chlorothiazide, chlortalidone and indapamide (for amlodipine), be specified as therapeutic alternatives under the square box listing for telmisartan + hydrochlorothiazide on the EML.